Chimerix (CMRX) Competitors

$0.91
+0.03 (+3.39%)
(As of 04/22/2024 ET)

CMRX vs. BTAI, ETON, PMVP, ONCY, AFMD, QTTB, HOOK, YS, SPRO, and CLSD

Should you be buying Chimerix stock or one of its competitors? The main competitors of Chimerix include BioXcel Therapeutics (BTAI), Eton Pharmaceuticals (ETON), PMV Pharmaceuticals (PMVP), Oncolytics Biotech (ONCY), Affimed (AFMD), Q32 Bio (QTTB), Hookipa Pharma (HOOK), YS Biopharma (YS), Spero Therapeutics (SPRO), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical preparations" industry.

Chimerix vs.

BioXcel Therapeutics (NASDAQ:BTAI) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

In the previous week, BioXcel Therapeutics had 12 more articles in the media than Chimerix. MarketBeat recorded 14 mentions for BioXcel Therapeutics and 2 mentions for Chimerix. Chimerix's average media sentiment score of 0.71 beat BioXcel Therapeutics' score of 0.51 indicating that BioXcel Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioXcel Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Chimerix
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BioXcel Therapeutics presently has a consensus target price of $16.86, indicating a potential upside of 491.48%. Chimerix has a consensus target price of $8.00, indicating a potential upside of 775.37%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Chimerix is more favorable than BioXcel Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioXcel Therapeutics
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43
Chimerix
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Chimerix received 150 more outperform votes than BioXcel Therapeutics when rated by MarketBeat users. However, 67.05% of users gave BioXcel Therapeutics an outperform vote while only 64.12% of users gave Chimerix an outperform vote.

CompanyUnderperformOutperform
BioXcel TherapeuticsOutperform Votes
236
67.05%
Underperform Votes
116
32.95%
ChimerixOutperform Votes
386
64.12%
Underperform Votes
216
35.88%

30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 35.8% of BioXcel Therapeutics shares are owned by company insiders. Comparatively, 10.0% of Chimerix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Chimerix has lower revenue, but higher earnings than BioXcel Therapeutics. Chimerix is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioXcel Therapeutics$1.38M63.15-$179.05M-$6.15-0.46
Chimerix$320K254.78-$82.10M-$0.92-0.99

BioXcel Therapeutics has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.

BioXcel Therapeutics has a net margin of -12,974.86% compared to BioXcel Therapeutics' net margin of -25,337.96%. BioXcel Therapeutics' return on equity of -37.93% beat Chimerix's return on equity.

Company Net Margins Return on Equity Return on Assets
BioXcel Therapeutics-12,974.86% -890.63% -144.88%
Chimerix -25,337.96%-37.93%-35.02%

Summary

Chimerix beats BioXcel Therapeutics on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMRX vs. The Competition

MetricChimerixPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$81.53M$6.37B$4.74B$7.34B
Dividend YieldN/A3.11%5.56%3.98%
P/E Ratio-0.9917.33259.0620.29
Price / Sales254.78304.802,584.0483.30
Price / CashN/A19.0131.9127.23
Price / Book0.425.494.584.22
Net Income-$82.10M$139.46M$101.64M$213.35M
7 Day Performance-0.67%-2.29%-1.36%-0.42%
1 Month Performance-8.59%-9.16%-6.72%-5.10%
1 Year Performance-24.47%-0.48%8.38%4.76%

Chimerix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BTAI
BioXcel Therapeutics
4.3849 of 5 stars
$2.68
-2.5%
$16.86
+529.0%
-87.1%$81.95M$1.38M-0.4474
ETON
Eton Pharmaceuticals
2.3873 of 5 stars
$3.19
-0.9%
$10.00
+213.5%
-9.0%$81.95M$31.64M-106.3330Positive News
PMVP
PMV Pharmaceuticals
1.8782 of 5 stars
$1.60
-1.8%
$5.67
+254.2%
-63.7%$82.30MN/A-1.1063Gap Down
ONCY
Oncolytics Biotech
0.8121 of 5 stars
$1.08
+1.9%
$4.00
+270.4%
-11.1%$81.45MN/A-3.6029News Coverage
AFMD
Affimed
3.4756 of 5 stars
$5.34
-2.7%
$45.00
+742.7%
-41.1%$81.33M$8.95M-0.64219Negative News
QTTB
Q32 Bio
1.1008 of 5 stars
$24.99
-5.5%
$47.50
+90.1%
N/A$80.72M$1.16M-0.71N/AGap Down
HOOK
Hookipa Pharma
3.703 of 5 stars
$0.81
+6.6%
$5.17
+537.9%
-7.0%$80.14M$20.13M-0.9256
YS
YS Biopharma
3.037 of 5 stars
$0.85
-4.5%
$5.25
+514.9%
-55.4%$79.46M$100M0.00754Positive News
Gap Down
SPRO
Spero Therapeutics
4.4755 of 5 stars
$1.47
-3.9%
$7.00
+376.2%
-17.4%$79.19M$103.78M3.5046Positive News
Gap Up
CLSD
Clearside Biomedical
3.024 of 5 stars
$1.15
-10.9%
$4.75
+313.0%
+33.0%$85.93M$8.23M-2.1730Gap Down

Related Companies and Tools

This page (NASDAQ:CMRX) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners